Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Increased RNA polymerase III activity in cancer has been observed for over 30 years but how this occurs and affects cellular transformation is only beginning to be understood. Lynne Marshall and Robert J. White discuss recent progress made in this emerging field.
The recent determination of the structure of the class I phosphoinositide 3-kinase PI3Kα has identified important structural differences between the class 1 PI3Ks. How can this information be used to improve cancer therapy?
CDC37 is oncogenic because it stabilizes the structures of mutated or overexpressed oncogenic kinases. Targeting this chaperone activity, on which many tumours depend, is therefore an attractive option for broad-based therapy.